Lipid metabolism, amino acid metabolism, and prostate cancer: a crucial metabolic journey.
Journal
Asian journal of andrology
ISSN: 1745-7262
Titre abrégé: Asian J Androl
Pays: China
ID NLM: 100942132
Informations de publication
Date de publication:
26 Dec 2023
26 Dec 2023
Historique:
received:
16
06
2023
accepted:
08
10
2023
medline:
2
1
2024
pubmed:
2
1
2024
entrez:
29
12
2023
Statut:
aheadofprint
Résumé
Prostate cancer (PCa) is one of the most common malignancies in males worldwide, and its development and progression involve the regulation of multiple metabolic pathways. Alterations in lipid metabolism affect the proliferation and metastatic capabilities of PCa cells. Cancer cells increase lipid synthesis and regulate fatty acid oxidation to meet their growth and energy demands. Similarly, changes occur in amino acid metabolism in PCa. Cancer cells exhibit an increased demand for specific amino acids, and they regulate amino acid transport and metabolic pathways to fulfill their proliferation and survival requirements. These changes are closely associated with disease progression and treatment response in PCa cells. Therefore, a comprehensive investigation of the metabolic characteristics of PCa is expected to offer novel insights and approaches for the early diagnosis and treatment of this disease.
Identifiants
pubmed: 38157428
doi: 10.4103/aja202363
pii: 00129336-990000000-00150
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Copyright: © 2023 The Author(s)(2023).
Références
Malinowski B, Wicinski M, Musiala N, Osowska I, Szostak M. Previous, current, and future pharmacotherapy and diagnosis of prostate cancer-a comprehensive review. Diagnostics (Basel) 2019;9:161.
Berlin A, Brierley J, Cornford P, Chung P, Giannopoulos E, et al. TNM staging of prostate cancer:challenges in securing a globally applicable classification. Eur Urol 2022;82:e52–3.
Shpilsky J, Stevens J, Bubley G. An up-to-date evaluation of abiraterone for the treatment of prostate cancer. Expert Opin Pharmacother 2021;22:1227–34.
Uemura H, Kobayashi K, Yokomizo A, Hinotsu S, Horie S, et al. Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study. Int J Clin Oncol 2022;27:1632–43.
Stepka P, Vsiansky V, Raudenska M, Gumulec J, Adam V, et al. Metabolic and amino acid alterations of the tumor microenvironment. Curr Med Chem 2021;28:1270–89.
Pardo JC, Ruiz de Porras V, Gil J, Font A, Puig-Domingo M, et al. Lipid metabolism and epigenetics crosstalk in prostate cancer. Nutrients 2022;14:851.
Zheng M, Wang W, Liu J, Zhang X, Zhang R. Lipid metabolism in cancer cells. Adv Exp Med Biol 2021;1316:49–69.
Jia J, Che L, Cigliano A, Wang X, Peitta G, et al. Pivotal role of fatty acid synthase in c-myc driven hepatocarcinogenesis. Int J Mol Sci 2020;21:8467.
Chow RY, Jeon US, Levee TM, Kaur G, Cedeno DP, et al. PI3K promotes basal cell carcinoma growth through kinase-induced p21 degradation. Front Oncol 2021;11:668247.
Chuang HY, Lee YP, Lin WC, Lin YH, Hwang JJ. Fatty acid inhibition sensitizes androgen-dependent and -independent prostate cancer to radiotherapy via FASN/NF-kappaB pathway. Sci Rep 2019;9:13284.
Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, et al. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 2010;70:390–400.
Rohrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer 2016;16:732–49.
Butler LM, Mah CY, Machiels J, Vincent AD, Irani S, et al. Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Res 2021;81:4981–93.
Berchuck JE, Adib E, Abou Alaiwi S, Dash AK, Shin JN, et al. The prostate cancer androgen receptor cistrome in african american men associates with upregulation of lipid metabolism and immune response. Cancer Res 2022;82:2848–59.
Wang H, Liu Z, Wang Y, Han D, Du Y, et al. Comprehensive analysis of fatty acid metabolism-related gene signatures for predicting prognosis in patients with prostate cancer. Peer J 2023;11:e14646.
Xu H, Li S, Sun Y, Xu L, Hong X, et al. ELOVL5-mediated long chain fatty acid elongation contributes to enzalutamide resistance of prostate cancer. Cancers (Basel) 2021;13:3957.
Ma Y, Zha J, Yang X, Li Q, Zhang Q, et al. Long-chain fatty acyl-CoA synthetase 1 promotes prostate cancer progression by elevation of lipogenesis and fatty acid beta-oxidation. Oncogene 2021;40:1806–20.
Chen HW, Chang YF, Chuang HY, Tai WT, Hwang JJ. Targeted therapy with fatty acid synthase inhibitors in a human prostate carcinoma LNCaP/tk-luc-bearing animal model. Prostate Cancer Prostatic Dis 2012;15:260–4.
Icard P, Wu Z, Fournel L, Coquerel A, Lincet H, et al. ATP citrate lyase:a central metabolic enzyme in cancer. Cancer Lett 2020;471:125–34.
Qiu Z, Deng W, Hong Y, Zhao L, Li M, et al. Biological behavior and lipid metabolism of colon cancer cells are regulated by a combination of sterol regulatory element-binding protein 1 and ATP citrate lyase. Onco Targets Ther 2021;14:1531–42.
Shah S, Carriveau WJ, Li J, Campbell SL, Kopinski PK, et al. Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism. Oncotarget 2016;7:43713–30.
Gao Y, Islam MS, Tian J, Lui VW, Xiao D. Inactivation of ATP citrate lyase by cucurbitacin B:a bioactive compound from cucumber, inhibits prostate cancer growth. Cancer Lett 2014;349:15–25.
Zu XY, Zhang QH, Liu JH, Cao RX, Zhong J, et al. ATP citrate lyase inhibitors as novel cancer therapeutic agents. Recent Pat Anticancer Drug Discov 2012;7:154–67.
Raab S, Lefebvre T. Fatty acid synthase, a “multi-FASet”enzyme. Med Sci (Paris) 2022;38:445–52.
Cheng J, Ondracek RP, Mehedint DC, Kasza KA, Xu B, et al. Association of fatty-acid synthase polymorphisms and expression with outcomes after radical prostatectomy. Prostate Cancer Prostatic Dis 2015;18:182–9.
Huang SY, Huang GJ, Hsieh PF, Wu HC, Huang WC. Osajin displays potential antiprostate cancer efficacy via impairment of fatty acid synthase and androgen receptor expression. Prostate 2019;79:1543–52.
Penfold L, Woods A, Muckett P, Nikitin AY, Kent TR, et al. CAMKK2 promotes prostate cancer independently of AMPK via increased lipogenesis. Cancer Res 2018;78:6747–61.
Gang X, Yang Y, Zhong J, Jiang K, Pan Y, et al. P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth. Oncotarget 2016;7:15135–49.
Lee J, Walsh MC, Hoehn KL, James DE, Wherry EJ, et al. Regulator of fatty acid metabolism, acetyl coenzyme a carboxylase 1, controls T cell immunity. J Immunol 2014;192:3190–9.
Wang C, Ma J, Zhang N, Yang Q, Jin Y, et al. The acetyl-CoA carboxylase enzyme:a target for cancer therapy?. Expert Rev Anticancer Ther 2015;15:667–76.
Luo DX, Peng XH, Xiong Y, Liao DF, Cao D, et al. Dual role of insulin-like growth factor-1 in acetyl-CoA carboxylase-alpha activity in human colon cancer cells HCT-8:downregulating its expression and phosphorylation. Mol Cell Biochem 2011;357:255–62.
Liu S, Lai J, Feng Y, Zhuo Y, Zhang H, et al. Acetyl-CoA carboxylase 1 depletion suppresses de novo fatty acid synthesis and mitochondrial beta-oxidation in castration-resistant prostate cancer cells. J Biol Chem 2023;299:102720.
Ueda K, Nakatsu Y, Yamamotoya T, Ono H, Inoue Y, et al. Prolyl isomerase Pin1 binds to and stabilizes acetyl CoA carboxylase 1 protein, thereby supporting cancer cell proliferation. Oncotarget 2019;10:1637–48.
Furuhashi M. Fatty acid-binding protein 4 in cardiovascular and metabolic diseases. J Atheroscler Thromb 2019;26:216–32.
O'Sullivan SE, Kaczocha M. FABP5 as a novel molecular target in prostate cancer. Drug Discov Today 2020;25:2056–61.
Nitschke K, Erben P, Waldbillig F, Abdelhadi A, Weis CA, et al. Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5. World J Urol 2020;38:637–45.
Senga S, Kobayashi N, Kawaguchi K, Ando A, Fujii H. Fatty acid-binding protein 5 (FABP5) promotes lipolysis of lipid droplets, de novo fatty acid (FA) synthesis and activation of nuclear factor-kappa B (NF-κB) signaling in cancer cells. Biochim Biophys Acta Mol Cell Biol Lipids 2018;1863:1057–67.
Kikuchi K, Tsukamoto H. Stearoyl-CoA desaturase and tumorigenesis. Chem Biol Interact 2020;316:108917.
Kim SJ, Choi H, Park SS, Chang C, Kim E. Stearoyl CoA desaturase (SCD) facilitates proliferation of prostate cancer cells through enhancement of androgen receptor transactivation. Mol Cells 2011;31:371–7.
Fritz V, Benfodda Z, Rodier G, Henriquet C, Iborra F, et al. Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther 2010;9:1740–54.
Contreras-Lopez EF, Cruz-Hernandez CD, Cortes-Ramirez SA, Ramirez-Higuera A, Pena-Montes C, et al. Inhibition of stearoyl-CoA desaturase by sterculic oil reduces proliferation and induces apoptosis in prostate cancer cell lines. Nutr Cancer 2022;74:1308–21.
Furth PA. Peroxisome proliferator-activated receptor gamma and BRCA1. Endocr Relat Cancer 2019;26:R73–9.
Zhang H, Meng S, Lin L, Wu Q, Zhou R, et al. [Effects of peroxisome proliferator-activated receptors gamma on the expression of insulin receptor substrate-4 gene in rat cortical neurons and mouse brain. Nan Fang Yi Ke Da Xue Xue Bao 2013;33:1463–6 [Article in Chinese].
Olokpa E, Moss PE, Stewart LV. Crosstalk between the androgen receptor and PPAR gamma signaling pathways in the prostate. PPAR Res 2017;2017:9456020.
Olokpa E, Bolden A, Stewart LV. The androgen receptor regulates PPARgamma expression and activity in human prostate cancer cells. J Cell Physiol 2016;231:2664–72.
Hartley A, Ahmad I. The role of PPARgamma in prostate cancer development and progression. Br J Cancer 2023;128:940–5.
Reiss AB, De Leon J. Special issue on “advances in cholesterol and lipid metabolism”. Metabolites 2022;12:765.
Rantaniemi L, Tammela TL, Kujala P, Murtola TJ. Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy. Scand J Urol 2018;52:269–76.
Celhay O, Bousset L, Guy L, Kemeny JL, Leoni V, et al. Individual comparison of cholesterol metabolism in normal and tumour areas in radical prostatectomy specimens from patients with prostate cancer:results of the CHOMECAP study. Eur Urol Oncol 2019;2:198–206.
Skara L, Hudek Turkovic A, Pezelj I, Vrtaric A, Sincic N, et al. Prostate cancer-focus on cholesterol. Cancers (Basel) 2021;13:4696.
Wang X, Sun B, Wei L, Jian X, Shan K, et al. Cholesterol and saturated fatty acids synergistically promote the malignant progression of prostate cancer. Neoplasia 2022;24:86–97.
Da Silveira RA, Hermes CL, Almeida TC, Bochi GV, De Bona KS, et al. Ischemia-modified albumin and inflammatory biomarkers in patients with prostate cancer. Clin Lab 2014;60:1703–8.
Di Maso M, Augustin LS, Jenkins DJ, Carioli G, Turati F, et al. Adherence to a cholesterol-lowering diet and the risk of prostate cancer. Food Funct 2022;13:5730–8.
Hai Q, Smith JD. Acyl-coenzyme A:cholesterol acyltransferase (ACAT) in cholesterol metabolism:from its discovery to clinical trials and the genomics era. Metabolites 2021;11:543.
Goudarzi A. The recent insights into the function of ACAT1:a possible anti-cancer therapeutic target. Life Sci 2019;232:116592.
Lee SS, Li J, Tai JN, Ratliff TL, Park K, et al. Avasimibe encapsulated in human serum albumin blocks cholesterol esterification for selective cancer treatment. ACS Nano 2015;9:2420–32.
Shafqat N, Turnbull A, Zschocke J, Oppermann U, Yue WW. Crystal structures of human HMG-CoA synthase isoforms provide insights into inherited ketogenesis disorders and inhibitor design. J Mol Biol 2010;398:497–506.
Yeo SG, Kim DY, Kim KH, Ku JL, Kim JS, et al. Hydroxymethylglutaryl-coenzyme a synthase 2 expression is associated with chemoradiotherapy responses in colorectal cancer. Dis Colon Rectum 2012;55:686–94.
Ashida S, Kawada C, Inoue K. Stromal regulation of prostate cancer cell growth by mevalonate pathway enzymes HMGCS1 and HMGCR. Oncol Lett 2017;14:6533–42.
Hwang S, Hartman IZ, Calhoun LN, Garland K, Young GA, et al. Contribution of accelerated degradation to feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase and cholesterol metabolism in the liver. J Biol Chem 2016;291:13479–94.
Hoy SM. Pitavastatin:a review in hypercholesterolemia. Am J Cardiovasc Drugs 2017;17:157–68.
Huang J, Zhao X, Li X, Peng J, Yang W, et al. HMGCR inhibition stabilizes the glycolytic enzyme PKM2 to support the growth of renal cell carcinoma. PLoS Biol 2021;19:e3001197.
Orho-Melander M, Hindy G, Borgquist S, Schulz CA, Manjer J, et al. Blood lipid genetic scores, the HMGCR gene and cancer risk:a mendelian randomization study. Int J Epidemiol 2018;47:495–505.
Basavaraj P, Ruangsai P, Hsieh PF, Jiang WP, Bau DT, et al. Alpinumisoflavone exhibits the therapeutic effect on prostate cancer cells by repressing AR and co-targeting FASN- and HMGCR-mediated lipid and cholesterol biosynthesis. Life (Basel) 2022;12:1769.
Li Y, Chen S, Zhu J, Zheng C, Wu M, et al. Lovastatin enhances chemosensitivity of paclitaxel-resistant prostate cancer cells through inhibition of CYP2C8. Biochem Biophys Res Commun 2022;589:85–91.
Tan P, Zhang C, Wei SY, Tang Z, Gao L, et al. Effect of statins type on incident prostate cancer risk:a meta-analysis and systematic review. Asian J Androl 2017;19:666–71.
Albrecht W. Highlight report:role of choline phospholipid metabolism in tumor progression. EXCLI J 2019;18:1097–8.
Keshari KR, Tsachres H, Iman R, Delos Santos L, Tabatabai ZL, et al. Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage –impact of tissue environment. NMR Biomed 2011;24:691–9.
Henderson V, Smith B, Burton LJ, Randle D, Morris M, et al. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression. Cell Adh Migr 2015;9:255–64.
Voelkel-Johnson C, Norris JS, White-Gilbertson S. Interdiction of sphingolipid metabolism revisited:focus on prostate cancer. Adv Cancer Res 2018;140:265–93.
Marin-Aguilera M, Pereira MV, Jimenez N, Reig O, Cuartero A, et al. Glutamine and cholesterol plasma levels and clinical outcomes of patients with metastatic castration-resistant prostate cancer treated with taxanes. Cancers (Basel) 2021;13:4960.
Matos A, Carvalho M, Bicho M, Ribeiro R. Arginine and arginases modulate metabolism, tumor microenvironment and prostate cancer progression. Nutrients 2021;13:4503.
Pichler R, Fritz J, Heidegger I, Steiner E, Culig Z, et al. Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer. Cancer Sci 2017;108:663–70.
Gao X, Locasale JW, Reid MA. Serine and methionine metabolism:vulnerabilities in lethal prostate cancer. Cancer Cell 2019;35:339–41.
Selvi I, Basar H, Baydilli N, Murat K, Kaymaz O. The importance of plasma arginine level and its downstream metabolites in diagnosing prostate cancer. Int Urol Nephrol 2019;51:1975–83.
Zoni E, Minoli M, Bovet C, Wehrhan A, Piscuoglio S, et al. Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification. BMC Cancer 2019;19:1216.
Strmiska V, Michalek P, Eckschlager T, Stiborova M, Adam V, et al. Prostate cancer-specific hallmarks of amino acids metabolism:towards a paradigm of precision medicine. Biochim Biophys Acta Rev Cancer 2019;1871:248–58.
Pal S, Sharma A, Mathew SP, Jaganathan BG. Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics. Front Immunol 2022;13:955476.
Yoo HC, Yu YC, Sung Y, Han JM. Glutamine reliance in cell metabolism. Exp Mol Med 2020;52:1496–516.
Yang L, Venneti S, Nagrath D. Glutaminolysis:a hallmark of cancer metabolism. Annu Rev Biomed Eng 2017;19:163–94.
Thiruvalluvan M, Billet S, Bhowmick NA. Antagonizing glutamine bioavailability promotes radiation sensitivity in prostate cancer. Cancers (Basel) 2022;14:2491.
Zhang Y, Li J, Huang Y, Chen Y, Luo Z, et al. Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1. Theranostics 2023;13:578–95.
Chen CL, Hsu SC, Ann DK, Yen Y, Kung HJ. Arginine signaling and cancer metabolism. Cancers (Basel) 2021;13:3541.
Yang M, Zhang Y, Liu G, Zhao Z, Li J, et al. TIPE1 inhibits osteosarcoma tumorigenesis and progression by regulating PRMT1 mediated STAT3 arginine methylation. Cell Death Dis 2022;13:815.
El Gaafary M, Morad SAF, Schmiech M, Syrovets T, Simmet T. Arglabin, an EGFR receptor tyrosine kinase inhibitor, suppresses proliferation and induces apoptosis in prostate cancer cells. Biomed Pharmacother 2022;156:113873.
Grifka-Walk HM, Jenkins BR, Kominsky DJ. Amino acid trp:the far out impacts of host and commensal tryptophan metabolism. Front Immunol 2021;12:653208.
Gehin M, Welford RW, Garzotti M, Vercauteren M, Groenen PM, et al. Assessment of peripheral serotonin synthesis using stable isotope-labeled tryptophan. Clin Pharmacol Ther 2018;104:1260–7.
Duitama M, Moreno Y, Santander SP, Casas Z, Sutachan JJ, et al. TRP channels as molecular targets to relieve cancer pain. Biomolecules 2021;12:1.
Zhong T, Zhang W, Guo H, Pan X, Chen X, et al. The regulatory and modulatory roles of TRP family channels in malignant tumors and relevant therapeutic strategies. Acta Pharm Sin B 2022;12:1761–80.
Shinka T, Onodera D, Tanaka T, Shoji N, Miyazaki T, et al. Serotonin synthesis and metabolism-related molecules in a human prostate cancer cell line. Oncol Lett 2011;2:211–5.
Rodriguez-Blanco G, Burgers PC, Dekker LJ, Vredenbregt-van den Berg MS, Ijzermans JN, et al. Serum kynurenine/tryptophan ratio is not a potential marker for detecting prostate cancer. Clin Biochem 2014;47:1347–8.
Khan A, Choi SA, Na J, Pamungkas AD, Jung KJ, et al. Noninvasive serum metabolomic profiling reveals elevated kynurenine pathway's metabolites in humans with prostate cancer. J Proteome Res 2019;18:1532–41.
Izzo S, Naponelli V, Bettuzzi S. Flavonoids as epigenetic modulators for prostate cancer prevention. Nutrients 2020;12:1010.
Tong D, Zhang J, Wang X, Li Q, Liu L, et al. MiR-22, regulated by MeCP2, suppresses gastric cancer cell proliferation by inducing a deficiency in endogenous s-adenosylmethionine. Oncogenesis 2020;9:99.
Zhang W, Zhang Z, Wu H, Xu K, Yuan W, et al. Update analysis on the association between methionine synthase rs1805087 A/G variant and risk of prostate cancer. Sci Rep 2020;10:13384.
Han Q, Tan Y, Hoffman RM. Oral dosing of recombinant methioninase is associated with a 70% drop in PSA in a patient with bone-metastatic prostate cancer and 50% reduction in circulating methionine in a high-stage ovarian cancer patient. Anticancer Res 2020;40:2813–9.
Yu KM, Pang TP, Cutler M, Tian M, Huang L, et al. Rational design, engineer, and characterization of a novel pegylated single isomer human arginase for arginine depriving anti-cancer treatment. Life Sci 2021;264:118674.
Lu WC, Saha A, Yan W, Garrison K, Lamb C, et al. Enzyme-mediated depletion of serum l-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity. Proc Natl Acad Sci U S A. 2020;117:13000–11.